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Abstract
Objective—The role of host-derived tissue factor (TF) in tumor growth, angiogenesis and
metastasis has hitherto been unclear, and was investigated in this study.
Methods—We compared tumor growth, vascularity and responses to cyclophosphamide (CTX)
of tumors in wild type (wt) mice, or in animals with TF levels reduced by 99% (low-TF mice).
Results—Global growth rate of three different types of transplantable tumors (LLC, B16F1 and
ES teratoma), or metastasis were unchanged in low-TF mice. However, several unexpected tumor/
context-specific alterations were observed in these mice, including: (i) reduced tumor blood vessel
size in B16F1 tumors; (ii) larger spleen size and greater tolerance to CTX toxicity in the LLC
model; (iii) aborted tumor growth after inoculation of TF-deficient tumor cells (ES TF-/-) in low-
TF mice. TF-deficient tumor cells grew readily in mice with normal TF levels, and attracted
exclusively host-related blood vessels (without vasculogenic mimicry). We postulate that this
complementarity may result from tumor-vascular transfer of TF-containing microvesicles, as we
observed such transfer using human cancer cells (A431) and mouse endothelial cells, both in vitro
and in vivo.
Conclusions—Our study points to an important, but context-dependent role of host TF in tumor
formation, angiogenesis and therapy.
INTRODUCTION
Several experimental studies point to the antitumor effects of genetic and pharmacological
blockade of the coagulation system including tumor-cell associated tissue factor (TF) 1;2,
and often through interference with angiogenesis 3-6. However, other reports suggest that TF
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expression by cancer cells is of little (or no) consequence for tumor aggressiveness 7;8. For
instance, experiments with murine embryonic stem (ES) cells with either intact (TF+/-) or
disrupted (TF-/-) TF gene originally led Toomey et al to conclude that subcutaneous
teratomas could be efficiently generated irrespectively of the TF status of tumor forming
(ES) cells 7. A possible explanation of this conundrum could lie in the observation that TF
may be expressed by various subsets of host cells often present in the tumor mass, including,
stromal fibroblasts, inflammatory cells and the endothelium, all likely involved in regulation
of angiogenesis 9, but this possibility has not been explored directly.
The effects of TF on vascular cells could be mediated through localized procoagulant effects
of this receptor, irrespectively of its cellular source, leading to the generation of factor Xa
and thrombin, followed by the deposition of fibrin and activated platelets 2;10. However, the
effects of TF could also be more cell autonomous in nature, and driven by changes in
intracellular signaling 11. In this case the co-expression of TF and protease activated
receptors (PARs) could trigger signals mediated by thrombin (via PAR-1), or by TF/VIIa
complex 11-13, including interactions between the cytoplasmic tail of TF and PAR-2
receptor in endothelial cells 14. Interestingly, deletion of the latter domain in transgenic mice
altered (increased) their vascular responses in the context of tumors and developing retina
14. However, the angiogenic consequences associated with the obliteration of the entire TF
molecule in the host compartment of a growing tumor are still to be examined.
In this regard, studies on host-related TF have been hampered by the embryonic lethality
associated with TF gene disruption in mice, and with limitations of the available mouse-
specific pharmacological antagonists of this receptor. Moreover, such agents tend to target
selectively some (procoagulant), but not all biological activities of TF 15, e.g. may not
obliterate TF-dependent signaling 11. One way to circumvent these difficulties is to take
advantage of a unique strain of mice, in which the endogenous mouse TF gene (mTF) is
substituted with a human minigene (hTF) giving rise to the expression of a severely
hypomorphic TF phenotype (low-TF mice) 16. Homozygous low-TF mice (mTF-/-/hTF+/+)
are viable, but unlike their wild type (mTF +/+), or heterozygous (mTF+/-/hTF+/-)
counterparts express only 1% of the expected TF activity, encoded exclusively by the hTF
sequence 16. We chose low-TF mice to examine the effects of host-TF on tumor
angiogenesis.
Here we show that the growth of three different types of TF-expressing transplantable
tumors was unchanged in low-TF mice, as compared to that in their TF-proficient
counterparts. However, host TF does exert a number of context-dependent effects, including
on blood vessel size in some, but not all tumors. Importantly, in the absence of tumor-related
TF the growth of tumors in low-TF mice was completely aborted. We propose that TF plays
a crucial role in tumor formation, and it can be shared between tumor and host compartment
through exchange of membrane microvesicles.
MATERIALS AND METHODS
Cells and culture conditions
Lewis Lung Carcinoma (LLC), B16F1 melanoma and A431 human squamous cell
carcinoma cells were purchased from American Type Tissue Collection (ATCC, Manassas,
VA, USA). The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM;
HyClone, Logan, Utah, USA) supplemented with 10% Fetal Bovine Serum (FBS;
Invitrogen, Carlsbad, CA, USA). Mouse brain endothelial cells (MBE) were cultured on 1%
gelatin coated dishes in EGM2 medium, as previously described 17;18. The labeling of A431
cell surface and related microvesicles with the PKH26 dye (Sigma, San Diego, CA) was
conducted as previously described 6;19. MTF+/- and TF-/- ES cells were generated as
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detailed elsewhere 7, as were the wild type ES cells (R1) and their LacZ (C16) and YFP
(YC5)-tagged derivatives, a generous gift of Dr. Andras Nagy, University of Toronto 20. All
ES cells were maintained on gelatinized (0.1%) culture plates in the presence of mitomycin
C treated fibroblasts (MEFs; DR4 from American Tissue Culture Collection, Manassas, VA)
containing 2ME, non essential amino acids, leukemia inhibitory factor (LIF/ESGRO,
Millipore, Billerica, MA; 500 U), 15% pre-tested fetal bovine serum (Hyclone) and with
frequent feeding and subculturing. The cells were passaged several times without MEFs
before injection into mice 20.
Northern analysis
Expression of TF transcripts was analysed as described earlier 6. The membranes were
examined using the Typhoon 9410 Phosphoimager (Amersham Biosciences) and
autoradiographed.
Mice
Low-TF mice were described previously 16. For tumor studies the mice were backcrossed
into either C57BL/6 (LLC, B16F1), or (ES-teratoma) severe combined immunodeficiency
(SCID) background.
Tumor generation and analysis
Tumorigenic cells were collected and injected subcutaneously in 0.1 ml of phosphate
buffered saline (PBS), at the following predetermined numbers: 7-10 × 105 (LLC), 2 × 106
(B16F1) and 107 (ES cells) under isoflurane anesthesia (1 – 3%). Tumor growth was
monitored as described earlier 20. All in vivo experiments were conducted approved by the
institutional Animal Care Committees at McMaster and McGill Universities and in
accordance with the Canadian Council of Animal Care (CCAC) guidelines.
Therapy
Cyclophosphamide (CTX; Procytox, ASTA Medica, Ltd.) was used according to previously
published maximal tolerated dose (MTD) and low dose/metronomic (LD) protocols 21.
Under the MTD regimen the drug was injected at 150 mg/kg on days: 2, 4 and 6 post tumor
cell inoculation, and then on days: 23, 25 and 27. Increase in mortality occurred after the
first round of injections. For metronomic (LD) therapy the drug was injected at the dose of
150 mg/kg on day 2 post tumor inoculation and then daily at 25 mg/kg 21. A monoclonal
anti-human TF antibody (TF8-5G9; Centocor Inc.; 5 mg/kg) or vehicle was injected
intraperitoneally into low-TF mice (hTF) harboring LLC tumors (mTF) 3 times a week
beginning on day 2 post tumor cell inoculation.
Experimental metastasis
A single cell suspension of 105 LLC cells/0.2 ml PBS was injected into the pre-warmed
dilated lateral tail veins of the respective wild type, or low-TF syngeneic C56BL/6 mice, as
indicated. Mice were sacrificed after 28 days and autopsied. Lungs were excised preserved
in Bouin’s fixative, and surface nodules were counted under a dissecting microscope, as
described 22.
Tissue staining
Microvasculature of tumors was assessed by immunostaining for endothelial (CD31/
PECAM; CD105/endoglin), or pericyte markers (αSMA), as described elsewhere 23.
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The experiments were repeated 2-5 times, mostly 3 times, with similar results. The number
of experimental mice per group in all in vivo studies varied between 4-10 for each
experiment. The results were expressed as mean +/- SD for each group. Unpaired Student t
tests were used to examine the differences between groups. Probability values <0.05 were
considered significant unless otherwise stated.
RESULTS
Host TF and blood vessel patterning in melanoma
In syngeneic mice, B16F1 mouse melanoma cells form rapidly growing tumors containing
cuffs of viable malignant parenchyma clustering around distinctly large (15-30μm) blood
vessels, in which endothelial layers are covered with well-differentiated pericytes, as
determined by staining for CD31/PECAM (or CD105/endoglin) and alpha smooth muscle
actin (αSMA), respectively (Fig. 1A). These host cells are known to express TF 13. Injection
of B16F1 cells into mice with intact TF levels (mTF+/-) or into their hypomorphic, low-TF
counterparts resulted in indistinguishable rate of tumor formation (Fig. 1B), however the
tumor vascular microarchitecture has undergone a significant rearrangement (Fig. 1C). Thus,
in low-TF mice tumor blood vessels were still covered with pericytes, but for the most part
were considerably smaller in size (mostly < 15μm in diameter) than those in TF-proficient
mice (both mTF+/+ and mTF+/-).
Unchanged, growth, vascularity and metastasis of Lewis Lung Carcinoma (LLC) in low-TF
mice
Similarly to B16F1 melanoma, LLC cells form aggressive tumors in vivo, but with vastly
different vascular patterns. A defining feature in this case is the absence of large vessels and
a dense network of small capillaries (<15μm), largely devoid of SMA-reactive pericytes
(Fig. 2A). While the TF content of LLC tumors increases in vivo, possibly with some
contribution of host TF (Fig. 2B), the latter does not influence LLC progression or
angiogenesis, as tumor growth, experimental metastasis and vascular patterns were virtually
identical in wild type (mTF+/+), heterozygous (mTF+/-) and low-TF mice (Fig. 2CD, data
not shown). Tumor growth remained unchanged even when tumor-bearing, low-TF mice
were treated with an anti-human TF antibody (TF8-5G9), which would selectively obliterate
the residual host TF (encoded by the hTF transgene), but not tumor/LLC-related (mouse) TF
16 (Fig. 2C).
Host-related TF modulates toxic side effects of cyclophosphamide
Anti-cancer agents often trigger procoagulant events 24. We asked whether host TF may
play a role in this context, or in responses to other prototypic therapies such as
administration of cyclophosphamide (CTX) at maximal tolerated doses (MTD), or at
antiangiogenic/metronomic, low doses (LD), both previously validated in the LLC model 21.
As shown in Fig. 3A, the responses of LLC tumors to MTD or LD protocols of CTX were
unaffected by the host TF status. Interestingly, MTD therapy led to some mortality, but only
in TF-proficient (mTF+/-) tumor bearing mice and not in their low-TF counterparts (Fig.
3B). Moreover, we observed that untreated low TF (SCID) mice exhibit markedly larger
spleens than their mTF+/+ or mTF+/- controls (Fig. 3CD). This was also the case in LLC
tumor bearing mice, where low TF hosts contained more extensive lymphocytic infiltrates in
areas surrounding white pulp. While CTX treatment reduced spleen size and cellularity in all
mice, low TF mice retained greater amounts of spleen mass and white pulp nodules (Fig.
3E-I). Interestingly, these mice also had reduced fibrin deposition in their kidney (not
shown). This may suggest that low levels of host TF may have a protective role against
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some of the side effects of anticancer therapy, likely through a combination of coagulation-
dependent and hematopoietic effects that remain to be elucidated.
Host TF expression is essential for growth of TF-deficient teratomas
In agreement with the aforementioned results subcutaneous injection of TF-expressing and
tumorigenic embryonic stem (ES) cells led to unperturbed formation of aggressive and
angiogenic teratomas in both wild type and low-TF mice (Fig. 4)23. In this case the mice
were backcrossed to the SCID background to avoid immune rejection. It is of note that the
model of ES teratoma afforded us a unique opportunity to interrogate TF depletion in both
the host and tumor cell compartments simultaneously, e.g. by including TF-/- ES cells 7 and
low-TF mice. Thus, we observed that both TF+/- and TF-/- ES cells grew as vascular
teratomas in SCID mice with wild type levels of TF7. Remarkably, this process was
selectively aborted in the case of TF-/- ES cells (but not TF+/- cells) injected into low-TF
SCID mice (Fig. 4B). This result suggests that TF is essential for the malignant teratoma
growth to occur, and this requirement can be met through TF contribution by either tumor,
or host cells.
ES cell-derived teratomas recruit host blood vessels
The aforementioned result is novel and potentially important. However, totipotential
capacity of ES cells to differentiate 25 may imply that tumor blood vessels may in this case
originate from tumor (ES) cells and not through recruitment of host endothelium, a
phenomenon known as vasculogenic mimicry 26. Indeed, ES teratomas contain complex
mixtures of histological elements including abnormal capillaries (Fig. 4C-E). To
unequivocally distinguish tumor (ES) and host (mouse)-derived elements we used several
molecular tags, including: yellow and green fluorescent proteins (YFP and GFP), as well as
beta galactosidase (LacZ; Fig. 4C-H). Thus, TF-proficient (mTF+/+) ES cells (R1) tagged
with LacZ were injected into untagged SCID mice, and we determined that all tumor-
associated, CD31-positive endothelial cells originated from the LacZ-negative host
compartment (Fig. 4F). We also generated teratomas from unlabelled ES cells that were
injected into YFP/SCID mice harboring a constitutively expressed YFP transgene23. Again,
staining for CD105 and YFP revealed dual positivity (host origin) of all tumor-associated
blood vessels (Fig. 4G). Finally, YFP-labeled ES cells were used to generate tumors in
untagged SCID mice and, again, we observed essentially no overlap between YFP and
CD105 staining, except for a solitary blood vessel found in one section (Fig. 4H). This
enforces the notion that ES teratomas, like many other cancers, rely on recruitment of the
host-derived vasculature, which may serve as a source of TF to support growth of TF-/-
tumors shown in Fig. 4B
Endothelial cell uptake of tumor-related TF-containing microvesicles
The aforementioned experiments (Fig. 4B) raise the possibility that TF activity may be
shared between tumor and host cell compartments. One mechanism by which this could
occur is through intercellular exchange of TF containing microvesicles (MVs) 27-29. To test
this, we employed the human epithelial carcinoma cell line, A431, which produces ample
amounts of TF (Fig. 5A), which is also shed into conditioned medium as membrane MVs 28.
To test, whether this material could, indeed, be transferred to endothelial cells, the
membranes of A431 cells were labeled with the fluorescent dye (PKH26) and their
conditioned medium (containing MVs) was incubated with TF-negative mouse brain
endothelial cells (MBEs). This led to a lasting acquisition by the latter cells of PKH26
fluorescence, human TF antigen expression (not shown) and TF-dependent procoagulant
activity (Fig. 6AB), all derived from A431 tumor cells. These changes did not occur when
A431-derived material was depleted from the MV fraction by high-speed centrifugation 28.
Moreover, host blood vessels in A431 xenografts in SCID mice were positive for both
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human TF (Fig. 5 E-G) and endothelial markers (CD105), suggesting the intercellular
transfer of TF taking place in vivo (Fig. 5H).
DISCUSSION
In this study we report several new findings related to the role of host TF in tumor
angiogenesis and progression. Notably, we provide evidence that TF expression may be
essential for tumorigenesis, at least in some settings, since a simultaneous depletion of this
receptor from both tumor and host compartments led to a complete arrest of tumor
formation. The nature of this effect remains presently unknown, but may include thrombin-
dependent and/or independent, essential effects of TF on hemostasis, and/or on signaling in
endothelial, stromal and/or tumor cells 11;13. In spite of this uncertainty, our results may
reconcile the long standing controversy, as to whether TF contributes to primary tumor
growth and angiogenesis 3-6;30;31, or is irrelevant for these processes 7;8. Using the same
TF-/- ES cell lines 7 that have originally led to the latter notion we demonstrated that the
removal of TF from cancer cells may, at least in some cases, be insufficient to block tumor
formation, notably due to compensatory effects of the host-derived TF (and vice versa). We
propose that this TF ‘sharing’ between tumor and host compartments could occur through
the exchange of TF containing microvesicles, as recently described for inflammatrory cells
and platelets 29. In particular, we suggest that such TF transfer could contribute to
procoagulant and proangiogenic reprogramming of endothelial cells in TF expressing
tumors 9 (Fig 5E). In addition, our study provides an important validation of the widely used
ES teratoma model, by documenting the absence of ES-derived blood vessels (vasculogenic
mimicry) in these tumors.
Unlike ES cells, many cancer cell types express TF under influence of oncogenic alterations
6. We postulate that in such a context tumor-derived TF may assume a dominant role in
tumorigenesis and can be targeted therapeutically, as recently demonstrated by Versteeg 32
and others 3;6;33. In these settings host-related TF makes a minimal quantitative contribution
to local growth or metastasis, as documented by our experiments with several mouse tumor
models (LLC, B16F1).
Interestingly, low levels of host TF led to qualitative re-patterning of the tumor
microvasculature in B16F1 melanoma. We suggest that lack of similar effects in other
tumors tested, is due to their a priori small caliber vasculature. It is unclear how host TF
may impact blood vessel patterning. While thrombin and PAR-1 were implicated as
regulators of vascular development 12;13, our injections of B16F1 cells into PAR-1-/- mice
did not recapitulate the vascular patterns observed in low-TF mice (unpublished
observation). While tumors in low-TF mice were of unchanged size, it is possible that
vascular re-patterning may influence angiogenic pathways in a qualitative manner, and
impact other vascular aspects of tumourigenesis, such as metastasis and therapeutic
responses.
We were intrigued by the partial protection of LLC tumor bearing, low-TF mice from the
toxicity of high doses (MTD) of CTX. This effect was unlikely due to a differential drug
distribution, pharmacodynamics, or direct toxicity against tumor cells. In this regard,
prothrombotic effects of anticancer chemotherapeutics are well established, including in the
clinic 2;34. These events may be attributed to endothelial injury 35;36, suppression of the
protein C pathway 24, upregulation of TF and decrease in levels of the tissue factor pathway
inhibitor (TFPI)37. Indeed, we observed a lower fibrin deposition in kidneys of CTX-treated
tumor bearing low-TF mice (data not shown). These mice demonstrated larger spleens
containing greater reserves of lymphocytic cells, relative to their wild type counterparts.
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This finding may suggest a hitherto unappreciated role of TF in modulating hematopoietic
toxicity of CTX.
Collectively, our findings reveal several novel properties of host TF. We suggest that a
complex role of this receptor in tumor growth, angiogenesis, vascular patterning and drug
toxicity has been previously obscured by exclusion of host TF from experimental studies.
We observed that the effects of host-related TF are highly context dependent and different in
tumors driven by aberrant differentiation (teratoma) or genetic aberrations (mouse
melanoma, lung carcinoma). Therefore, defining a universal role for TF in cancer may prove
elusive and targeting this receptor in various tumor settings may require a better
understanding of cellular sources of TF and their specific contributions to the malignant
process. Still, our study suggests that TF, in its cell-associated and microvesicular forms,
may represent an attractive anticancer target, at least in some settings, especially as a
regulator of tumor growth and/or modulator of anticancer drug toxicity.
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Figure 1. Growth and vascular patterning of B16F1 melanoma in low-TF mice
A. Distinct vascular pattern of B16F1 tumors in wild type C57BL/6 mice. Dilated blood
vessels contain a well defined, CD31-positive endothelial lining (left panel) and a thick,
continuous layer of αSMA-positive pericytes (right panel, green fluorescence). Inset, double
immunofluorescent staining of B16F1 related blood vessels for endothelial (endoglin/
CD105, green) and pericytic (αSMA, red) markers. B. Unchanged tumor growth kinetics of
B16F1 tumors in TF-proficient (TF+/-) and low-TF mice (n = 5; mean∀ SD). The former
mice represent crosses where one hypomorphic TF allele represents the hTF minigene and
one (mTF) is endogenous to the wild type mouse. In low-TF mice both TF alleles are
hypomorphic (hTF). C. Altered vascular architecture of B16F1 tumors in low-TF mice.
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Diminution of larger vessels (30-45 μm in diameter) and preponderance of small capillaries
(< 15 μm) in tumors growing in low-TF mice, but not in their wild type, or heterozygous
(TF+/-) counterparts (αSMA staining).
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Figure 2. Unchanged growth and metastasis of LLC tumors in low-TF mice
A. Preponderance of small, CD31-positive and αSMA-negative capillaries within LLC
tumors in wild type C57BL/6 mice. B. Increased expression of TF mRNA in vivo. C.
Unchanged growth kinetics of LLC tumors in untreated low-TF mice and in the presence of
the host-TF-specific (anti-hTF) neutralizing antibody (TF8-5G9; n = 5, mean ∀ SD). D.
Indistiguishable capacity of LLC cells to form experimental lung nodules in wild type
(wtTF) and low-TF mice (n = 7, mean ∀ SD).
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Figure 3. Unchanged antitumor responses, diminished chemotherapy-related mortality and
abnormal spleens in low-TF mice harboring LLC tumors
A. Both maximal tolerated (MTD) and low/metronomic (LD) regimens of
cyclophosphamide are similarly effective in TF-proficient (TF+/-) and low-TF mice. B.
Treatment-related mortality of LLC bearing mice subjected to MTD regimen was averted in
low-TF mice (n = 5 mice/group, mean ∀ SD; representative experiment out of 2 similar
repeats). C-D. Spleen weight and diameter in mTF+/+, mTF+/- and low TF in untreated
(SCID) mice. E-I. Spleen diameter * - p # 0.05; (E) and morphology (F-I) in LLC bearing
mice 24 hours after the last dose of MTD CTX vs controls. Noticeable are lymphocytic
infiltrates (ly) in low TF mice with retention of white pulp (wp) – H&E staining.
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Figure 4. Complementary roles of host- and tumor-related tissue factor during formation of ES
cell derived teratomas
A. Expression of TF mRNA by TF+/- and TF-/- ES cells. B. Tumor growth upon inoculation
of TF-/- and TF+/- ES cells into TF-proficient (SCID) or low-TF/SCID (TF-deficient)
strains. Only a simultaneous diminution of TF expression in both tumor and host cells led to
obliteration of teratoma formation. C. Morphology of ES-derived teratomas (H & E
staining). D. Comparable expression of markers of endothelial (CD105) and pericytic
(αSMA) cells in blood vessels in TF+/- and TF-/-teratomas growing in SCID mice. F. Non-
overlapping staining for ES cell (LacZ) and endothelial (CD31) markers in LacZ expressing
wild type teratomas G. Co-expression of host (YFP) and endothelial (CD105) markers in
wild type teratoma growing in the strain of SCID mice constitutively expressing the YFP
transgene (SCID/YFP) 23. Arrows point to cells expressing both markers. H. Non-
overlapping expression of ES cell associated (YFP) and endothelial (CD105) markers in
tumors originating from YFP expressing ES cells in SCID mice (see text). Inset - rare blood
vessels containing markers of ES cells (YFP) in the endothelium.
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Figure 5. Microvesicle-mediated sharing of TF between tumor and endothelial cells
A. TF gene expression by human and murine tumor cell lines. B. Fluorescent labeling of
microvesicles (MVs) derived from A431 cancer cells using the PKH26 dye and (C) their
transfer to cultured mouse brain endothelial cells (MBE). D. Procoagulant reprogramming of
MBE cells by the uptake of tumor cell derived TF, via MV transfer. CM – A431 conditioned
media containing TF-rich MVs, Control treatments: Sup – A431 CM depleted of MVs;
DME10 – A431 growth medium (DMEM with 10%FBS); EGM2 – endothelial growth
medium; E-G. Uptake of human TF (red) in vivo by mouse endothelial cells stained for
CD105 (green) within A431 xenografts in SCID mice (G – overlay). H. Proposed
consequences of TF sharing between tumor and host compartments.
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